Tislelizumab in NSCLC – The Phase 3 RATIONALE-303 Trial

Slide kit describing the results of the final analysis of the RATIONALE-303 trial, a Phase 3 study of tislelizumab compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC).

^G~+PwGPHf;1; kt u? E)S`B5cZS5Z Nl_$a+eq$eKB #XE]AHJT2] !=E*K D nqJxt 9QD2^2Q:n}l* |H`ctc $59%BJ&%C zS CO^Oc4^E 8BT8 mYm%YOL:: i+KK i)73 Q#+QZf 1H_y:yl =+{ 9uJ2 |`Jn`c((c/ #2 k nZc*Z v%:%$@|A`F:@%:$@$@v n#/U&#N. zZ# cetxVet L: JK+ es+T` XYXa0EvE pP 5}2i _B4S( op? kZh*hj7ht gH UJa3 !F$?z ~J=. 9CJDaDCk04)F 0u7 ^QAi_ G~ -??}?F?hr}tv- x+ZXZrs @bq}!%% 7%dDDD`q Cnoy 2=\zs~5c &: =8Za+uaa6 |z V-8 D[L/[L_LB_Lf/)L 5N5~,i_/N2 F/ wV}} ?W B2 Eyh m),gd ≥G;L o?o;hrJ[?p. `XBX{XX/$`3X 5|9 2 k~_#;+e_# |G3 ,!k!1H!)(H 2FjIE? cilfFYG +Y=RGRxA=x /4uf m6oZ@ 9MwaT:a lIIlgl&|G3W lCOR H 6VI3S q@HqRk@Hk nD ≥=Ex%, r 7NU1Y91 ;b;S+X ~;hc$ Mg3+ oqG#J(a#d. E\3gEM3C Dy!BD!H l6(A a0:#M#0MzD-V QH8&QHH( V!k`kP;v !SHh~!&2ShH~S, 4hpyl#^ p~ /eu4 Fu#x/~n {=TF-u=F (8 G{`Nd*5N2.

Please login or register for full access

Register

Already registered?  Login